PURPOSE: The aims of this study were to: (1) estimate the volumetric and metabolic growth rate of non-small cell lung cancer (NSCLC), (2) evaluate disease progression prior to treatment, and (3) explore the effects of tumor growth rate and time to treatment (TTT) on survival outcome. METHODS: Patients with inoperable stages I-III NSCLC with serial pre-treatment PET/CT scans were eligible for this study. PET-derived metabolic tumor volumes (PET-MTV) and CT-derived gross tumor volumes (CT-GTV) were contoured using PET/CT information. Normalized standardized uptake values (NSUV) in tumors including the NSUVmean and NSUVmax were measured. Tumor growth rates expressed as doubling time (DT) were estimated using an exponential model. Pre-treatment disease progression defined as the development of any new site of disease on PET/CT and change in TNM stage (AJCC 7th ed.) were recorded. Growth rate and tumor progression were analyzed with respect to overall (OS) and progression free survival (PFS). RESULTS: Thirty-four patients with a median inter-scan interval (ISI) of 43 days and TTT of 48 days were analyzed. Tumor volumes showed remarkable inter-scan growth while NSUV did not increase significantly. The DT for PET-MTV, CT-GTV, NSUVmean and NSUVmax were 124, 139, 597, and 333 days, respectively. Pre-treatment disease progression occurred in 20.6% patients with longer ISI being a significant risk factor (OR=1.027, p=0.02). The optimal threshold ISI to predict progression was 58 days (4.8% vs. 46.2%, p=0.007). Neither tumor growth rates nor TTT were significantly correlated to OS or PFS. CONCLUSIONS: NSCLC displays rapid tumor volume growth whereas NSUVmean and NSUVmax are relatively stable over the same time period. Longer delays before initiation of treatment are associated with higher risk of pre-treatment disease progression. Published by Elsevier Ireland Ltd.
PURPOSE: The aims of this study were to: (1) estimate the volumetric and metabolic growth rate of non-small cell lung cancer (NSCLC), (2) evaluate disease progression prior to treatment, and (3) explore the effects of tumor growth rate and time to treatment (TTT) on survival outcome. METHODS:Patients with inoperable stages I-III NSCLC with serial pre-treatment PET/CT scans were eligible for this study. PET-derived metabolic tumor volumes (PET-MTV) and CT-derived gross tumor volumes (CT-GTV) were contoured using PET/CT information. Normalized standardized uptake values (NSUV) in tumors including the NSUVmean and NSUVmax were measured. Tumor growth rates expressed as doubling time (DT) were estimated using an exponential model. Pre-treatment disease progression defined as the development of any new site of disease on PET/CT and change in TNM stage (AJCC 7th ed.) were recorded. Growth rate and tumor progression were analyzed with respect to overall (OS) and progression free survival (PFS). RESULTS: Thirty-four patients with a median inter-scan interval (ISI) of 43 days and TTT of 48 days were analyzed. Tumor volumes showed remarkable inter-scan growth while NSUV did not increase significantly. The DT for PET-MTV, CT-GTV, NSUVmean and NSUVmax were 124, 139, 597, and 333 days, respectively. Pre-treatment disease progression occurred in 20.6% patients with longer ISI being a significant risk factor (OR=1.027, p=0.02). The optimal threshold ISI to predict progression was 58 days (4.8% vs. 46.2%, p=0.007). Neither tumor growth rates nor TTT were significantly correlated to OS or PFS. CONCLUSIONS:NSCLC displays rapid tumor volume growth whereas NSUVmean and NSUVmax are relatively stable over the same time period. Longer delays before initiation of treatment are associated with higher risk of pre-treatment disease progression. Published by Elsevier Ireland Ltd.
Authors: Nasiruddin Mohammed; Larry Llyn Kestin; Inga Siiner Grills; Madhu Battu; Dwight Lamar Fitch; Ching-Yee Oliver Wong; Jeffrey Harold Margolis; Gary William Chmielewski; Robert James Welsh Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-13 Impact factor: 7.038
Authors: Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Henry D Tazelaar; Jayawant N Mandrekar Journal: Radiology Date: 2007-02 Impact factor: 11.105
Authors: Helen T Winer-Muram; S Gregory Jennings; Robert D Tarver; Alex M Aisen; Mark Tann; Dewey J Conces; Cristopher A Meyer Journal: Radiology Date: 2002-06 Impact factor: 11.105
Authors: David F Yankelevitz; William J Kostis; Claudia I Henschke; Robert T Heelan; Daniel M Libby; Mark W Pasmantier; James P Smith Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: K Usuda; Y Saito; M Sagawa; M Sato; K Kanma; S Takahashi; C Endo; Y Chen; A Sakurada; S Fujimura Journal: Cancer Date: 1994-10-15 Impact factor: 6.860
Authors: Feng-Ming Spring Kong; Kirk A Frey; Leslie E Quint; Randall K Ten Haken; James A Hayman; Marc Kessler; Indrin J Chetty; Daniel Normolle; Avraham Eisbruch; Theodore S Lawrence Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Maude Trepanier; Tiffany Paradis; Araz Kouyoumdjian; Teodora Dumitra; Patrick Charlebois; Barry S Stein; A Sender Liberman; Kevin Schwartzman; Franco Carli; Gerald M Fried; Liane S Feldman; Lawrence Lee Journal: J Gastrointest Surg Date: 2019-07-31 Impact factor: 3.452
Authors: Michael MacManus; Sarah Everitt; Tanja Schimek-Jasch; X Allen Li; Ursula Nestle; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Tokihiro Yamamoto; Sven Kabus; Cristian Lorenz; Erik Mittra; Julian C Hong; Melody Chung; Neville Eclov; Jacqueline To; Maximilian Diehn; Billy W Loo; Paul J Keall Journal: Int J Radiat Oncol Biol Phys Date: 2014-08-04 Impact factor: 7.038
Authors: Gary T Smith; Ahmad R Rahman; Ming Li; Brandon Moore; Hester Gietema; Giulia Veronesi; Pierre P Massion; Ronald C Walker Journal: PLoS One Date: 2015-09-17 Impact factor: 3.240
Authors: David Weller; Peter Vedsted; Chantelle Anandan; Alina Zalounina; Evangelia Ourania Fourkala; Rakshit Desai; William Liston; Henry Jensen; Andriana Barisic; Anna Gavin; Eva Grunfeld; Mats Lambe; Rebecca-Jane Law; Martin Malmberg; Richard D Neal; Jatinderpal Kalsi; Donna Turner; Victoria White; Martine Bomb; Usha Menon Journal: BMJ Open Date: 2016-07-25 Impact factor: 2.692